Search results :

Tobramycin

More information: STITCH, PubChem (stereo-specific compound: 1) and possibly Wikipedia

ATC Codes: J01GB01, S01AA12

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Cough increased 46.1% 47.3% x
Pharyngitis 38% 39.3% x
Sputum increased 37.6% 39.7% x
Asthenia 35.7% 39.3% x x x x
Rhinitis 34.5% 33.6% x
Dyspnoea very common, 12.4% - 33.7% 38.5% x x x
Body temperature increased very common, 12.4% - 32.9% 43.5% x x x x x x x x x x
Lung disorder 30.1% - 33.8% 31.3% x x x
Cough very common, 31.1% - 48.4% x x
Headache uncommon, 11.4% - 26.7% 32.1% x x x x x x x
Chest pain 26% 29.8% x
Haemoptysis very common, 12.4% - 19.4% 23.7% x x x
Anorexia 18.6% 27.9% x
Productive cough very common, 18.2% - 19.6% x x
Respiratory depression rare, 16.3% 15.3% x x x x
Asthma 15.9% 20.2% x
Function kidney decreased very common x
Vomiting common, 5.7% - 14% 22.1% x x x x x x x x x x
Abdominal pain 12.8% 23.7% x
Oropharyngeal pain 10.5% - 14% x x x
Nausea common, 7.5% - 11.2% 16% x x x x x x x x x x
Weight decreased 10.1% 15.3% x
Dysphonia very common, 3.8% - 13.6% 1.74% x x x
Red blood cell sedimentation rate increased 8.42% 5.22% x
Pain very common, 8.1% 12.6% x x x x x
Sinusitis 8.1% 9.2% x
Upper respiratory tract infection 6.8% - 8.6% x
Pulmonary function test decreased 6.8% - 8.1% x
Ear pain 7.4% 8.8% x
Nasal congestion common, 7.2% - 8.1% x x
Back pain 7% 8% x
Rales common, 6.2% - 18.9% 15.7% x x x
Dysgeusia common, 0.5% - 6.6% 6.9% x x x
Malaise 6.2% 5.3% x
Epistaxis common, 1.9% - 7% 0% - 6.5% x x x x
Dizziness common, 5.8% 7.6% x x x x x x x x
Lower respiratory tract infection 5.8% 8% x
Wheezing common, 5.26% - 6.8% 3.48% x x x
Diarrhoea common, 1.58% - 6.2% 0.87% - 10.3% x x x x x x x x x x x
Hyperventilation 5.4% 9.9% x
Rash rare — 2.3% - 5.4% 6.1% x x x x x x x x x x x
Bronchospasm common x x x
High frequency deafness common x x x
Vertigo common x x x x x x x
Ocular hyperaemia common x
Chest discomfort common, 2.9% - 6.5% x x
Ocular discomfort common x
Musculoskeletal chest pain common, 4.5% - 4.8% x x
Throat irritation common, 1.9% - 4.5% x x
Forced expiratory volume decreased 1% - 31.1% 28.7% x x
Bronchitis 2.63% 0.87% x
Pharyngolaryngeal pain 2.63% 1.74% x x x
Aphonia postmarketing, common x x x
Tonsillitis 2.11% 0% x
Blood glucose increased 0.5% - 2.9% x
Eosinophilia 1.58% 0% x x x x x x x
Immunoglobulins increased 1.58% 0% x
Conjunctival disorder uncommon x
Corneal abrasion uncommon x
Dermatitis uncommon x
Eyelid disorder uncommon x
Hypersensitivity uncommon x x x x x x x
Eye pruritus uncommon x
Keratitis uncommon x
Pruritus uncommon x x x x x x x x x x x
Tinnitus postmarketing — common x x x x x x x x x x x
Urticaria uncommon x x x x x x x x x
Conjunctival oedema uncommon x
Eye pain uncommon x
Dry skin uncommon x
Lacrimation increased uncommon x
Eyelid oedema uncommon x
Leukoderma uncommon x
Erythema of eyelid uncommon x
Madarosis uncommon x
Dry eye uncommon x
Vision blurred uncommon x
Eye discharge uncommon x
Serum creatinine increased uncommon x x
Foreign body sensation in eyes uncommon x
Visual impairment uncommon x
Anaphylactic shock rare x x x
Renal failure acute rare x
Nephritis interstitial rare x
Nervous system disorder postmarketing x x x
Ototoxicity postmarketing, rare x x x x x x
Nephrotoxicity rare x
Hearing impaired postmarketing, common x x
Agranulocytosis x x x x x x x
Anaemia x x x x x x x
Angioedema x x x
Apnoea x x x
Bone disorder x
Confusional state x x x
Connective tissue disorder x x
Deafness x
Dehydration x x x
Delirium x x x
Dermatitis exfoliative x x x x x x x
Eye disorder x
Gastrointestinal disorder x x
Hypocalcaemia x x x
Hypokalaemia x x x
Immune system disorder x x
Laryngitis x
Lethargy x x x x x x x
Leukocytosis x x x
Leukopenia x x x
Mediastinal disorder x x x x
Oliguria x x x x x x x
Paraesthesia x x x
Neuropathy peripheral x x x
Proteinuria x x x x x x
Renal failure x
Stomatitis x x x
Swelling x x x
Thrombocytopenia x x x x x x x
Thrombophlebitis x x
Erythema x x x
Urinary tract disorder x
Angiopathy x x
Hypophosphataemia x x x
Creatinine increased x
Hypomagnesaemia x x x
Muscular weakness x x x
Injection site pain x x x
Phosphatase alkaline increased x
Aspartate aminotransferase increased x x x
Unspecified disorder of skin and subcutaneous tissue x x x x
Hypouricaemia x x x
Myalgia x
Disorientation x x x
Neurotoxicity x x x x x x x
Eye irritation x
Ear roaring x x x x x x x
Creatinine low x
Hypoalbuminaemia x x x
Punctate keratitis x
Platelet count decreased x x x
Lacrimation x x
Rash maculo-papular x x x
Application site pain x x x
Metabolic syndrome x x x
Serum calcium decreased x x x
Nephropathy toxic x
Stinging x
Drug interaction x x x
Eyelids pruritus x
Infestation NOS x x
Ear and labyrinth disorders x x x
Eye allergy x
Local reaction x
Serum bilirubin increased x
Serum transaminase increased x x x
Ocular toxicity x x x
Deafness unilateral x
Cochlear toxicity x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

tobramycin / Tobrex

Side effects:5
Source:FDA

TOBRAMYCIN / TOBREX 0.3% OPHTHALMIC SOL

Side effects:6
Source:Health Canada

TOBRAMYCIN

Side effects:16
Source:FDA Structured Product Label

tobramycin / tobramycin

Side effects:32
Source:EMA

TOBRAMYCIN

Side effects:40
Source:FDA Structured Product Label

Tobramycin

Side effects:50
Source:FDA Structured Product Label

TOBRAMYCIN SULFATE / TOBRAMYCIN SULFATE

Side effects:29
Source:FDA

TOBRAMYCIN

Side effects:30
Source:FDA Structured Product Label

TOBRAMYCIN

Side effects:30
Source:FDA Structured Product Label

Tobramycin BP / TOBRAMYCIN PF

Side effects:44
Source:medicines.org.au

TOBRAMYCIN INJECTION

Side effects:45
Source:medicines.org.au

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label